TOURMALINE BIO INC (TRML) Stock Income Statement
NASDAQ:TRML - Nasdaq - US89157D1054 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 98.45M | 89.73M | 45.41M | 76.28M | 47.51M | |||
| Research and Development | 75.87M | 66.98M | 32.37M | 56.81M | 34.25M | |||
| Selling, General, and Administrative Expenses | 22.58M | 22.75M | 13.04M | 19.47M | 13.26M | |||
| Operating Income | -98.45M | -89.73M | -45.41M | -76.28M | -47.51M | |||
| Interest Income/Expense | N/A | N/A | N/A | 900.00K | 800.00K | |||
| Other Income/Expense | 15.58M | 16.52M | 3.29M | 1.68M | -1.13M | |||
| Non Recurring Items | N/A | N/A | N/A | -200.00K | N/A | |||
| Income Before Taxes | -82.87M | -73.21M | -42.12M | -73.89M | -47.83M | |||
| Net Income | -82.87M | -73.21M | -42.12M | -73.89M | -47.83M | |||
| EBITDA | -98.41M | -89.69M | -45.38M | -74.90M | -46.89M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.22 | -2.89 | -8.87 | -17.93 | -11.69 | |||
| Non GAAP EPS | -3.21 | -2.87 | N/A | -17.90 | -5.53 | |||
| Statistics | ||||||||
All data in USD